2021 CMSC Annual Meeting

Tag: FAAN

Poster-Quality of Life and Outcomes

The Importance of Specialty Pharmacy Services in Multiple Sclerosis Patient Care

Background: Johns Hopkins Specialty Pharmacy provides clinical services for eligible multiple sclerosis (MS) patients on oral and...

Read More

Poster-Psychosocial Factors

Attitudes Toward Biobanking Among Persons with MS

Background: Biobanks that collect and preserve biological samples linked to demographic, phenotypic and clinical data are a critical...

Read More

Poster-Programs

The Influence of Tethered and Joint HCP and Patient Education on Clinical Practice Behavior, Patient Activation, and Empowerment

Background: Advances in disease-modifying therapies (DMT) for multiple sclerosis (MS) have left clinicians challenged to incorporate DMTs,...

Read More

Poster-Multidisciplinary Care

Health Resource Utilization Among Individuals with Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Background: The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a physician-based longitudinal registry of...

Read More

Poster-Internet and Information Services

MS and COVID-19: A Webinar Series for Healthcare Providers

Background: MS is a complex disease that requires a well- educated workforce. The COVID-19 pandemic added to that complexity- from the lack...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More

Poster-Disease-modifying Therapy

Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Poster-Case Reports / Case Series

Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate

Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to reduce...

Read More

Platform-Rehabilitation

Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.

Background: People with moderate-to-severe multiple sclerosis (MS) and their family caregivers do not engage in sufficient physical...

Read More